Abstract
A global pandemic requires accelerated strategies to mitigate public healthcare risks and preserve societal stability, either by repurposing existing drugs or by rapidly developing novel drug candidates. Computational platforms have accelerated candidate identification for both routes. A critical gap is the translation from in vitro potency to predicted clinical efficacy, which determines whether a prioritized candidate can achieve therapeutic effect under realistic dosing. To address this, we developed the Pandemic Pharmacology Platform for COMPUTational Evaluation of anti-infectives (PPP-COMPUTE), a comprehensive pharmacokinetic/pharmacodynamic (PK/PD) simulation platform designed to support evaluation and prioritization of drug candidates and clinical trial design during a pandemic. PPP-COMPUTE integrates experimentally derived anti-infective potency data (e.g., EC50) with PK/PD modeling to evaluate whether clinical dosing regimens can achieve sufficient exposure for therapeutic efficacy in patients. The platform incorporates mechanism-based dynamic models with a focus on viral pathogens to simulate time-dependent viral load trajectories under various treatment scenarios, enabling quantitative assessment of antiviral response and optimization of dosing strategies. Probability of target attainment analyses further support evaluation of regimen feasibility against predefined pharmacological targets. The clinical trial module generates simulated virological endpoints to evaluate candidate clinical study designs. PPP-COMPUTE is an accessible and quantitative framework that links PK and preclinical anti-infective potency data with predicted clinical benefit, thereby supporting rapid drug evaluation during future pandemics.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://github.com/LeidenPharmacology/pppcompute
Funder Information Declared
